Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy
about
Tendon development and musculoskeletal assembly: emerging roles for the extracellular matrixThe potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophyGalectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular DystrophyLaminin regulates PDGFRβ(+) cell stemness and muscle development.A splice site mutation in laminin-α2 results in a severe muscular dystrophy and growth abnormalities in zebrafishHanging on for the ride: adhesion to the extracellular matrix mediates cellular responses in skeletal muscle morphogenesis and diseaseLaminin therapy for the promotion of muscle regenerationPotent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.NAD+ biosynthesis ameliorates a zebrafish model of muscular dystrophy.Thrombospondin-4 controls matrix assembly during development and repair of myotendinous junctions.Substrate and strain alter the muscle-derived mesenchymal stem cell secretome to promote myogenesis.Laminin-111 improves skeletal muscle stem cell quantity and function following eccentric exerciseQuantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.Laminin-211 in skeletal muscle function.212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMDLaminin: loss-of-function studies.Axial and limb muscle development: dialogue with the neighbourhood.Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy.Chimeric protein repair of laminin polymerization ameliorates muscular dystrophy phenotype.Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160.Laminin differentially regulates the stemness of type I and type II pericytes.HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway.ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice.Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.Aberrant Caspase Activation in Laminin-α2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity.Muscular dystrophy meets protein biochemistry, the mother of invention.Laminin-521 Protein Therapy for Glomerular Basement Membrane and Podocyte Abnormalities in a Model of Pierson Syndrome.Treating pediatric neuromuscular disorders: The future is now.At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?Why is Skeletal Muscle Regeneration Impaired after Myonecrosis Induced by Viperid Snake Venoms?
P2860
Q26775671-5F04500B-601B-4C06-94BE-E7498C1D0DEAQ26827638-9745C67E-6D87-4DDD-BE59-61B2E8DFE0ADQ27318308-E7BB4987-0FEB-4D2C-A4D9-C279496DD7E2Q27318580-B7D911BA-6889-472F-8F1E-5089D2C327F4Q27322025-31F2DB42-233C-4931-9C65-6504265B6C88Q28087402-CAA74285-5B03-4042-8425-ACCE2CEFF62BQ28087548-6B6DA7AB-F1F8-413E-B493-A6765AFD61C3Q30841381-F2E96FA0-0AB3-451E-A92E-6D9540ABADE3Q31105806-AE97F3B3-D0B3-4E33-B3D1-BF6AD667FB3AQ33896985-E0BADBCD-DFD6-4F5C-AB89-12F7A5647A29Q33900539-7B0ED3B5-3171-4DDE-BA07-3AFC3A79C60AQ34109413-2EDB5F6B-A3BF-4CEA-8464-1B311A8574FEQ35201194-BD8E344B-F70F-4DA2-A288-45747FD8871BQ36531788-82E1F7A1-4B84-4601-ACAE-0202FC56A7B0Q37555754-693D7C62-7E4D-4605-9B3D-766DCC44A1A3Q38644294-34C9389B-AF6A-4176-984D-D17739321A28Q38815433-462997C8-9BE2-4B87-A72C-70429D5B6DA8Q38877226-72D29D85-12D8-4D16-AE2B-14923AE0FB7CQ38882098-0306D1A0-9207-41A2-AA46-71CAF41B018BQ38951841-4CB1CC41-4453-467F-9136-38A09F37F8FCQ39559269-02B26F6E-DE01-4B6E-B7D1-BD7150F939E8Q41881081-AF0B9D0A-74C3-49F8-AB92-57D05A1E878BQ42091026-7C1EB2D5-F585-439F-B58E-7F93ABBE91F1Q42323278-C6F9E003-8743-4DA8-927A-8703149EF925Q42374498-17D24B94-E846-4108-9B99-AA7BCCB66962Q45871995-9B08CCAC-F93A-4778-B40B-FCB3B4FDE049Q47164258-329C408E-0AB3-44A3-9557-E054C221D31AQ47345657-AEEC1DA6-CF8F-4901-9874-D319831AE255Q49571085-051A011A-3A32-49ED-B36D-602DAB988E5DQ51130563-F86C297D-D8B6-4788-BE8B-B0A24BD5D012Q52730886-D74E0231-024B-4C3A-B613-889464BD0F37Q52756417-3F4146F1-B564-4664-ABA3-1188135B9A33Q55361250-93052520-DD14-4BAD-A093-8A4ED61D87EDQ55421504-19099B5A-0871-432F-A161-42A3DE94FB28
P2860
Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@ast
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@en
type
label
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@ast
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@en
prefLabel
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@ast
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@en
P2093
P2860
P1476
Laminin-111 protein therapy re ...... congenital muscular dystrophy
@en
P2093
Bradley L Hodges
Jachinta E Rooney
Jolie R Knapp
P2860
P304
P356
10.1016/J.AJPATH.2011.12.019
P407
P577
2012-02-06T00:00:00Z